Effects of SM-13496, an atypical antipsychotic agent, on MK-801-induced learning deficit in rats

It is generally assumed that schizophrenia patients show cognitive impairment as well as positive symptoms and negative symptoms and that typical antipsychotics do not favorably affect cognitive impairment. In this study, the effects of a novel atypical antipsychotic agent SM-13496, on cognitive fun...

Full description

Saved in:
Bibliographic Details
Published inJournal of Pharmacological Sciences Vol. 94; no. suppl.2; p. 163
Main Authors Kumiko Tokuda, Takeo Ishiyama, Tomoko Horisawa, Satoko Toma, Yukihiro Ohno, Akira Ito
Format Journal Article
LanguageJapanese
Published The Japanese Pharmacological Society 2004
Online AccessGet full text

Cover

More Information
Summary:It is generally assumed that schizophrenia patients show cognitive impairment as well as positive symptoms and negative symptoms and that typical antipsychotics do not favorably affect cognitive impairment. In this study, the effects of a novel atypical antipsychotic agent SM-13496, on cognitive function was evaluated using a rat passive avoidance test. NMDA antagonist MK-801 (MK-0.05 mg/kg sc) significantly shortened the step-through latency in a test session. SM-13496 at 3 and 10 mg/kg (po) significantly improved MK-induced leaming deficit without affecting the latency in a training session. On the other hand, a typical antipsychotic haloperidol and atypical antipsychotics olanzapine, risperidone, clozapine and quetiapine did not show significant improvement in MK-induced leaming deficit, although tendency to improve was observed with risperidone, clozapine and quetiapine. These findings suggest that SM-13496, in addition to the antipsychotic activity, has a significant cognition improvement action, where its adrenergic alpha-2c blocking activity seems to be involved.
ISSN:1347-8613
1347-8648